// App-Quantinova.ai

e17097 : Understanding the treatment effect modification of mono- or combination PD-1/PD-L1 inhibitor therapies on survival outcomes in patients with metastatic renal cell carcinoma: What does the literature say?

Researchers

Presenter

  • Neha Sati

Principal Investigators

  • Devon J Boyne

  • Darren Brenner

  • Paul Arora

Medical Centers

  • McMaster University, Hamilton, ON, Canada

  • Cytel Inc., Toronto, Canada

  • Cytel Inc., Toronto, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • N/A

Biomarkers

  • Programmed cell death protein 1

  • Programmed death-ligand 1

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved